Switch to Crexont improves motor function in patients with Parkinson’s disease

Patients with Parkinson’s disease experienced more “good on” time, less “off” time and motor function improvements after a switch to 6 weeks of treatment with Crexont from another levodopa-based therapy, according to study findings.These data were presented as a pair of posters at the Advanced Therapeutics in Movement & Related Disorders Congress.